Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
暂无分享,去创建一个
K. Young | Z. Xu-Monette | O. Nielsen | M. Møller | C. Visco | R. Go | L. Pedersen | A. Orazi | O. Gadeberg | Mikael Frederiksen | T. Green | T. Mourits‐Andersen | L. Pedersen
[1] K. Young,et al. High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma , 2012, The American journal of surgical pathology.
[2] L. Medeiros,et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.
[3] A. Ariza,et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas , 2011, Histopathology.
[4] L. Staudt,et al. BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab , 2011, Clinical Cancer Research.
[5] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[6] L. Sehn. A decade of R-CHOP. , 2010, Blood.
[7] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Matija Snuderl,et al. B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.
[9] C. Copie-Bergman,et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[11] E. Obermann,et al. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma , 2009, Journal of Clinical Pathology.
[12] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[13] E. Obermann,et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.
[14] L. Mazzucchelli,et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. , 2009, Human pathology.
[15] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[16] W. Chan,et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A Rosenwald,et al. Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.
[18] L. Staudt,et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.
[19] Marylène Lejeune,et al. Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer‐assisted image analysis procedure , 2008, Journal of anatomy.
[20] Andrew Lister,et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Gascoyne,et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma , 2007, Leukemia & lymphoma.
[23] E. Schuuring,et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Siebert,et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. , 2006, The Journal of molecular diagnostics : JMD.
[25] I. Lossos,et al. Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Gaulard,et al. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. , 2006, Haematologica.
[27] L. Staudt,et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.
[28] Youli Zu,et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma , 2005, Leukemia & lymphoma.
[29] Kajia Cao,et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[30] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[31] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[32] P. Gaulard,et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.
[33] S. Barrans,et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[35] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[36] J Hermans,et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.
[37] D C Linch,et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. , 1996, Blood.